Akebia Ther (AKBA)vsZoetis Inc (ZTS)
AKBA
Akebia Ther
$0.50
-13.20%
HEALTHCARE · Cap: $195.78M
ZTS
Zoetis Inc
$82.96
+0.47%
HEALTHCARE · Cap: $33.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 4234% more annual revenue ($9.49B vs $219.06M). ZTS leads profitability with a 26.4% profit margin vs -13.5%. ZTS earns a higher WallStSmart Score of 56/100 (C).
AKBA
Avoid24
out of 100
Grade: F
ZTS
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AKBA.
Margin of Safety
+11.2%
Fair Value
$144.94
Current Price
$82.96
$61.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 75 in profit
Strong operational efficiency at 38.2%
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -74.9% — below average capital efficiency
Trading at 10.2x book value
Expensive relative to growth rate
Revenue declined 1.3%
Earnings declined 11.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AKBA
AKBA has a balanced fundamental profile.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 26.4% and operating margin at 38.2%.
Bear Case : AKBA
The primary concerns for AKBA are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.16 is elevated, increasing financial risk.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, PEG Ratio, Revenue Growth. Debt-to-equity of 2.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
AKBA profiles as a turnaround stock while ZTS is a declining play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.68 — expect wider price swings.
ZTS is growing revenue faster at -1.3% — sustainability is the question.
ZTS generates stronger free cash flow (717M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (56/100 vs 24/100), backed by strong 26.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akebia Ther
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?